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Abstract
Background: High mammographic density is associated with both risk of cancers being missed at mammography,
and increased risk of developing breast cancer. Stratification of breast cancer prevention and screening requires
mammographic density measures predictive of cancer. This study compares five mammographic density measures to
determine the association with subsequent diagnosis of breast cancer and the presence of breast cancer at screening.
Methods: Women participating in the “Predicting Risk Of Cancer At Screening” (PROCAS) study, a study of cancer
risk, completed questionnaires to provide personal information to enable computation of the Tyrer-Cuzick risk score.
Mammographic density was assessed by visual analogue scale (VAS), thresholding (Cumulus) and fully-automated
methods (Densitas, Quantra, Volpara) in contralateral breasts of 366 women with unilateral breast cancer (cases)
detected at screening on entry to the study (Cumulus 311/366) and in 338 women with cancer detected subsequently.
Three controls per case were matched using age, body mass index category, hormone replacement therapy use and
menopausal status. Odds ratios (OR) between the highest and lowest quintile, based on the density distribution in
controls, for each density measure were estimated by conditional logistic regression, adjusting for classic risk factors.
Results: The strongest predictor of screen-detected cancer at study entry was VAS, OR 4.37 (95% CI 2.72–7.03) in the
highest vs lowest quintile of percent density after adjustment for classical risk factors. Volpara, Densitas and
Cumulus gave ORs for the highest vs lowest quintile of 2.42 (95% CI 1.56–3.78), 2.17 (95% CI 1.41–3.33) and 2.12
(95% CI 1.30–3.45), respectively. Quantra was not significantly associated with breast cancer (OR 1.02, 95% CI 0.67–1.54).
Similar results were found for subsequent cancers, with ORs of 4.48 (95% CI 2.79–7.18), 2.87 (95% CI 1.77–4.64) and 2.34
(95% CI 1.50–3.68) in highest vs lowest quintiles of VAS, Volpara and Densitas, respectively. Quantra gave an OR in the
highest vs lowest quintile of 1.32 (95% CI 0.85–2.05).
Conclusions: Visual density assessment demonstrated a strong relationship with cancer, despite known inter-observer
variability; however, it is impractical for population-based screening. Percentage density measured by Volpara and
Densitas also had a strong association with breast cancer risk, amongst the automated measures evaluated, providing
practical automated methods for risk stratification.
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Background
High mammographic density, the relative proportion of
fibroglandular to fatty tissue in the breast, reduces the
effectiveness of mammographic screening [1–4] and in-
creases risk of developing breast cancer [5, 6]. The
relationship of density with risk was established using
expert visual assessment of film mammograms [7], with
computer-assisted methods providing more reproducible
estimates [8, 9]. With increasing uptake of full-field
digital mammography (FFDM), the association between
automated density assessment methods and cancer risk
is under investigation [10–12].
The most widely used method of assessing mammo-
graphic density in the USA is the Breast Imaging Report-
ing And Data System (BI-RADS) categorisation, where
experts assign mammograms to one of four classes, the
upper two being considered “dense”’ [13]. The class de-
scriptors were changed in 2013 to better identify women
whose cancers may be masked by dense parenchymal
tissue [14]. Visual assessment of percentage density may
be recorded on visual analogue scales (VAS), providing a
continuous measure. This yielded a strong relationship
with breast cancer risk for film mammograms, with an
odds ratio (OR) of approximately 7 for 76–100% density
relative to 0–25% [15]. Likewise, Boyd’s 6-class categor-
isation of percent visual density gave a relative risk in
the highest category (> 75% dense) compared with the
lowest of 6.05 (95% confidence interval (CI) = 2.82–
12.97) in a case-control study with 354 cases [8]. Cumu-
lus, a semi-automated thresholding method, was devel-
oped to improve reproducibility [8, 9] and has a well-
established relationship with cancer risk [8, 12]. How-
ever, this method also requires trained observers, and
whilst separating the breast from the mammogram back-
ground is reproducible, judgement of the best threshold
to separate dense tissue from fat is less so. Boyd cat-
egory, VAS and Cumulus are all relative, area-based
methods, so density estimates can vary depending on
breast positioning and patient weight [8, 16]. Weight
change disproportionately alters the fatty component of
the breast [17] and percentage density measures should
be adjusted to take body mass index (BMI) into account
[18].
Now that digital mammography is standard through-
out the UK, volumetric measures of mammographic
density, made by calibrating pixel values in the raw (“for
processing”) FFDM image using a model of x-ray physics
and imaging parameters [19], are now available. These
can be expressed either in percentage terms (volumetric
percent dense) or as absolute measures of dense and
non-dense tissue.
The availability of fully automated density assessment
paves the way for risk stratification in screening [20],
allowing selection of the most appropriate imaging
modality and screening frequency for the individual
[21, 22]. The addition of mammographic density to
breast cancer risk models based on other risk factors
has demonstrated increased predictive power, depend-
ing on the method used for density estimation [23–25].
It is therefore important to determine which density
methods are suitable for risk-adapted screening; more
accurate risk prediction will enable better targeting of
risk-reducing interventions including chemoprevention
and lifestyle modification [26, 27].
A previous case-control analysis, carried out in
London, compared density measured in the unaffected
(contralateral) breast in 414 women diagnosed with uni-
lateral breast cancer at one hospital with that of 685 un-
matched controls attending routine breast screening.
Comparing the highest percentage density quintile with
the lowest, and adjusting for age, BMI and reproductive
variables, the strongest association with risk of develop-
ing breast cancer was for Volpara, with an OR of 8.26
(95% CI 4.28–15.96), followed by Quantra, OR 3.94
(2.26–6.86) and Cumulus, OR 3.38 (2.00–5.72) [13].
However, mammographic density was assessed at the
time of detection of cancer, so the ability of density to
predict women who would later develop the disease was
not assessed. Here we address this by evaluating the as-
sociation between five mammographic density methods
and the presence of cancer at the time of screening, and
the association between four mammographic density
methods and cancer detected subsequently, either be-
tween screening rounds or at a later screen, using data
from the Predicting Risk of Cancer At Screening study
(PROCAS) [20].
Methods
Study design
Women invited to the Greater Manchester Breast
Screening Service for routine 3-yearly mammographic
screening between October 2009 and March 2015 were
also invited to participate in the “Predicting Risk Of
Cancer At Screening” (PROCAS) study, which aimed to
provide women with a personalised risk estimate of their
breast cancer risk based on mammographic density and
classic breast cancer risk factors obtained via a question-
naire and quantified by the Tyrer-Cuzick risk score [28].
After October 2012 only women attending their first
(prevalent round) screen were invited. At the time of re-
cruitment informed consent was obtained from all
participants.
In order to assess density using fully automated
methods, the raw FFDM (for processing) image data
from GE Senographe Essential mammography systems
was obtained. Cancers (invasive and ductal carcinoma in
situ) were identified through hospital records or through
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the North West Cancer Intelligence Service; women
who moved out the area were considered ineligible. Two
case-control datasets were created. In study 1, cases
were women with breast cancer detected at the screen
on entry to PROCAS and in study 2 cases were women
who were breast cancer free at the screen on entry to
PROCAS but had breast cancer detected subsequently,
either between screening rounds or at a later screen. In
these women we analysed the density of the screen on
entry to PROCAS.
Three controls without cancer were matched to each
cancer case based on age (±12 months), BMI category
(missing, < 24.9, 25.0–29.9, 30+ kg/m2), hormone re-
placement therapy (HRT) use (current vs never/ever)
and menopausal status (premenopausal, perimenopausal
or postmenopausal). In both studies all controls had a
subsequent cancer-free screening mammogram so it was
unlikely that early signs of cancer were visible, and in
study 2, controls were also matched on year of mammo-
gram at entry.
Mammographic density measurement
Visual estimation of percentage density
Processed FFDM images were displayed on Planar Dome
E5 5MP self-calibrating high-resolution monitors. Two
of nineteen readers (usually a consultant radiologist or
breast physician and an advanced practitioner radiog-
rapher) independently recorded density estimates on a
paper form showing four 10-cm horizontal VAS, one for
each view, labelled 0% and 100% at the ends of the scale.
Forms were read using custom software and visual per-
centage density calculated. VAS readings were averaged
between readers and views, and analysed in quintiles
and as Boyd categories (0%, > 0–10%, > 10–25%, > 25–
50%, > 50–75% and > 75%) [8]. Due to the small number
of cases in the highest category (three in study 1 and six
in study 2), the top two Boyd categories were combined
for analysis. Intra-observer and inter-observer agreement
for 120 mammograms randomly selected across deciles
of VAS density scores, from the PROCAS study, were
assessed by 11 readers, on two occasions, 3 years apart.
The majority of readers had excellent intra-observer
agreement (intraclass correlation coefficient (ICC) >
0.80), and inter-observer agreement for consistency was
excellent (ICC = 0.82) and was substantial for absolute
agreement (ICC = 0.69) [29].
Cumulus
Cumulus (Sunnybrook Health Sciences Centre, Toronto,
ON, Canada) density assessment was undertaken by a
single reader (JS) trained in August 2010 and validated
by a member of the PROCAS team (JW) who had
herself been trained by the group that developed the
software. Reader performance was validated on test sets
of data developed for this purpose by the trainers. Proc-
essed FFDM images were analysed. Cumulus was under-
taken on a single contralateral mediolateral oblique
(MLO) view of a subset of the study 1 dataset compris-
ing 311 screen-detected cancers and their matched con-
trols. The reader was blind to case-control status.
Quantra™
Quantra version 2.0 (Hologic Inc, Bedford, MA, USA)
was used to assess density from the raw FFDM images
for each view, each breast and each woman, giving
breast and fibroglandular tissue volume (cm3), and the
dense tissue area as a percentage of breast volume. It
also provides a quantized BI-RADS-like score for each
view and per breast.
Volpara™
Volpara Density Algorithm 1.5.0 (Volpara Health Tech-
nologies, Wellington, New Zealand) was also used to as-
sess density from the raw FFDM images for each view,
giving breast volume and fibroglandular tissue volume
(cm3) and percentage density by volume. Volpara pro-
vided a macro, which produced per-patient results in-
cluding Volpara Density Grade (VDG 4th and 5th
Edition), designed to correlate with BI-RADS 4th and 5th
Edition [15]. This also computes the percentage density
of the two breasts following outlier removal.
Densitas™
Densitas version 2.0.0 (Densitas Inc, Halifax, NS,
Canada) analyses processed FFDM images, giving breast
and fibroglandular area (cm2) and percentage density by
area for each image and per patient. It also produces
per-patient measures of BIRADS 4th and 5th edition [15].
Statistical methods
In study 1, mammographic density was assessed in the
contralateral breast in women with cancer and the breast
on the same side in matched controls, whereas in study
2, density was assessed in both breasts at entry to PRO-
CAS and the average was used.
Categorical data were compared using the chi-square
test for proportions. For ordinal variables, a chi-square
test for trend was also conducted. Continuous variables
were assessed by the median and Mann-Whitney U test.
The relationship between density assessment and case-
control status was analysed using conditional logistic re-
gression. Density measures were modelled as quintiles
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based on the density distributions of controls, and also
as continuous measures, transformed to approximately
follow a normal distribution (square root transformation
for VAS and Cumulus, and a logarithm transformation
for Volpara, Quantra and Densitas). Univariate models
were fitted initially, and multivariate models fitted to ad-
just for the logarithm 10-year Tyrer-Cuzick (v.6) risk
score. In study 2 we also adjusted for parity, due to im-
balance between cases and controls. We also performed
an analysis in a subset of women who had been assessed
using all density methods to determine which model
performed best and differences between models were
compared using the likelihood-ratio chi square. The
matched concordance (mC) index, a modification of the
concordance index (or area under the receiving operator
characteristic curve (AUC)) for matched case-control
studies, gives an average concordance index within
matched groups (where 1.0 would indicate perfect dis-
crimination after allowing for matching factors) with
empirical bootstrap confidence intervals [30], was calcu-
lated to compare the discrimination performance of risk
factors. All p values were two-sided. Analysis was per-
formed in SPSS version 22 [31] and R 3.3.1 [32].
Results
Of the 57,905 women recruited to PROCAS, raw FFDM
image data were available for 44,658 women (77%). Un-
availability of raw FFDM images was predominantly due
to the use of film mammography initially. There were
1004 cases of cancer occurring after consent up to No-
vember 2015, of which 704 were included in the analysis.
The excluded women comprised 39 women with a pre-
existing diagnosis of breast cancer, 13 with synchronous
bilateral breast cancer, 118 with film mammograms and
130 with FFDM but for which raw image data was un-
available. Of the 704 women eligible for the analysis, 366
were women with breast cancer detected at the screen on
entry to PROCAS (study 1) and 338 were women who
were found to be breast cancer free at the screen on
entry to PROCAS but had breast cancer detected sub-
sequently, either between screening rounds or at a later
screen (study 2). Of the latter, 114 women developed an
interval cancer within 5–46 months of entry (IQR 13–31)
and 224 women had breast cancer detected at a subse-
quent screen 17–55 months after entry (IQR 35–38).
Matching was satisfactory for both studies (Table 1).
There was a difference in 10-year Tyrer-Cuzick score,
with the score higher in cases (study 1, 2.95 vs 2.72, p
= 0.003; study 2: 2.91 vs 2.63, p < 0.001). The reported
rate of a previous breast biopsy in cases was 17.8%
(study 1) and 22.5% (study 2), and in controls it was
14.5% (study 1) and 15.1% (study 2). The difference in
biopsy rate between cases and controls was statistically
significant in study 2 (p = 0.005), but was similar (in
study 2) to the PROCAS study as a whole. In study 1
significantly fewer cases than controls reported being of
“white” ethnic origin (91.3% vs 94.5%, p = 0.003), and
fewer cases than controls reported having children in
study 2 (85.8% vs 90.2%, p = 0.023).
In study 1, VAS results were missing for 46 cases of
cancer, Quantra failed to produce results for one case
and one control, Volpara failed for one case, and Densi-
tas failed for 6 cases and 62 controls. In study 2 there
were missing density results for two cases of cancer
assessed by VAS, for one case and one control assessed
by Quantra and for 7 cases and 34 controls assessed by
Densitas.
Study 1: screen-detected cancers
In study 1 after full adjustment, the strongest predictor
of breast cancer risk was visually assessed density
(Table 2, Fig. 1), with an odds ratio (OR) of 4.37 (95% CI
2.72–7.03) in the highest quintile of density compared
with the lowest. When quantized in Boyd categories
(Table 3), the adjusted OR of those with greater than
50% density was 6.73 (95% CI 3.64–12.45) compared to
those with density 10% or lower. Volpara percent density
provided the next strongest association with cancer, with
an OR for the highest quintile of 2.42 (95% CI 1.56–
3.78) (Table 2, Fig. 1). When quantized in Volpara Dens-
ity Grades (VDG 5th edition), the OR of VDG4 was 4.39
(95% CI 2.28–8.48) compared with VDG1 (Table 3).
Both visually assessed density and Volpara percent dens-
ity showed a significant and clear trend with increasing
density (χ2 trend 35.6, p < 0.001 and 11.2, p < 0.001, re-
spectively). Percent density measured by Densitas and
Cumulus was also statistically significant (Table 2, Fig. 1),
with ORs of 2.17 (95% CI 1.41–3.33) and 2.12 (95% CI
1.30–3.45), respectively in the highest quintile of percent
density compared with the lowest, and for Quantra there
was no significant association (OR = 1.02, 95% CI 0.67–
1.54). The relationship with dense volume is shown in
Table 2; generally associations tended to be slightly
lower than those for percent density. In the subset of
women with all density measures VAS was a significantly
better predictor of breast cancer risk than all other
methods (Table 2, Additional file 1: Table S2). The
matched concordance index for VAS was 0.651 (95% CI
0.611–0.691) demonstrating better discrimination be-
tween cases and controls than all other methods
(Table 4).
Study 2: prior mammograms
In study 2 visually assessed density had the strongest as-
sociation with subsequent cancer in the fully adjusted
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models, with an OR of 4.48 (95% CI 2.79–7.18) in the
highest quintile of density compared with the lowest
(Table 2). When quantized in Boyd categories (Table 3),
the OR of those with density > 50% was 5.45 (95% CI
3.00–9.89) compared to those with density ≤ 10%. Vol-
para percent density had the next strongest association
with cancer, with an OR for the highest quintile of 2.87
(95% CI 1.77–4.64) (Table 2, Fig. 2). When quantized in
Volpara Density Grades (5th Edition), the OR of VDG4
was 3.00 (95% CI 1.54–5.86) compared with VDG1
(Table 3). Both visually assessed density and Volpara
percent density showed a dose response relationship
with increasing density (χ2 trend 42.7, p < 0.001 and
13.8, p < 0.001, respectively). For Densitas and Quantra,
those with percentage density in the highest quintile had
ORs of 2.34 (95% CI 1.50–3.68) and 1.32 (95% CI 0.85–
2.05), respectively (Table 2, Fig. 2). VAS predicted breast
cancer risk significantly better than all other density
methods in the subset of women who had density mea-
sured by all four methods (Table 2, Additional file 1:
Table S2). The matched concordance index for VAS was
0.647 (95% CI 0.607–0.688) demonstrating better dis-
crimination between cases and controls than all other
methods (Table 4).
Discussion
Visual assessment of breast density recorded on a VAS
was the strongest predictor of breast cancer risk, both in
the contralateral breast of women with screen-detected
cancers and in the average of bilateral mammographic
views prior to the detection of cancer. It is unlikely that
the presence of cancer influenced visual assessment in
study 1, since a blinded re-read of images from the
contralateral breast by four readers showed no evidence
of bias [23] and the ORs were similar to those in study
2. There is strong association between the VAS and
breast cancer despite known inter-observer variability
[32]; since the average VAS score of two readers was
used it is likely that cases falling into the top and bottom
quintiles of density do so unequivocally.
Volpara and Densitas percent density had the next
strongest associations with cancer in both studies, with
Table 2 Risk of developing breast cancer by density measures (highest versus the lowest quintilea (referent))
Subset with data for all methodsb
Univariate Adjustedc Univariate Adjustedc
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Study 1
1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent)
VAS (%) 4.45 (2.77–7.15) 4.37 (2.72–7.03) 5.61 (3.29–9.56) 5.44 (3.18–9.29)
Volpara gland volume (cm3) 2.13 (1.40–3.24) 2.09 (1.37–3.18) 2.00 (1.24–3.21) 1.97 (1.22–3.18)
Volpara breast density (%) 2.44 (1.57–3.80) 2.42 (1.56–3.78) 2.38 (1.45–3.91) 2.41 (1.46–3.97)
Cumulus dense area (cm2) 2.11 (1.32–3.38) 2.15 (1.34–3.45) 2.08 (1.28–3.27) 2.12 (1.30–3.45)
Cumulus breast density (%) 2.09 (1.29–3.40) 2.12 (1.30–3.45) 2.20 (1.32–3.64) 2.23 (1.34–3.71)
Quantra gland volume (cm3) 0.86 (0.58–1.30) 0.83 (0.55–1.25) 0.72 (0.45–1.15) 0.71 (0.44–1.13)
Quantra breast density (%) 1.05 (0.70–1.59) 1.02 (0.67–1.54) 1.11 (0.70–1.77) 1.08 (0.68–1.72)
Densitas dense area (cm2) 1.44 (0.96–2.16) 1.41 (0.93–2.12) 1.62 (1.01–2.59) 1.61 (1.00–2.58)
Densitas breast density (%) 2.30 (1.50–3.52) 2.17 (1.41–3.33) 2.19 (1.35–3.56) 2.10 (1.29–3.41)
Study 2
1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent)
VAS (%) 4.54 (2.86–7.22) 4.48 (2.79–7.18) 4.41 (2.76–7.06) 4.36 (2.70–7.04)
Volpara gland volume (cm3) 2.72 (1.79–4.14) 2.66 (1.74–4.08) 2.71 (1.77–4.14) 2.65 (1.72–4.09)
Volpara breast density (%) 2.78 (1.74–4.44) 2.87 (1.77–4.64) 2.61 (1.62–4.19) 2.71 (1.67–4.39)
Quantra gland volume (cm3) 1.36 (0.90–2.06) 1.28 (0.84–1.95) 1.32 (0.87–2.01) 1.24 (0.80–1.90)
Quantra breast density (%) 1.32 (0.86–2.03) 1.32 (0.85–2.05) 1.30 (0.84–2.00) 1.32 (0.85–2.05)
Densitas dense area (cm2) 2.34 (1.56–3.52) 2.23 (1.48–3.38) 2.29 (1.50–3.50) 2.14 (1.40–3.29)
Densitas breast density (%) 2.45 (1.57–3.82) 2.34 (1.50–3.68) 2.44 (1.56–3.80) 2.34 (1.49–3.66)
OR odds ratio, CI confidence interval, VAS visual analogue scale, results in italics indicate statistically significant results (p<0.05)
aQuintiles based on distribution amongst controls
bStudy 1: 239 cases with 3 controls, 62 with 2 controls and 2 with 1 control; study 2: 296 cases with 3 controls, 31 with 2 controls and 2 with 1 control
cAdjusted for Tyrer-Cuzick score; study 2 also adjusted for parity
Figures in italics denote statistically significant results p<0.01
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categorisation into VDG having the largest odds ratio.
Volpara, Quantra and Cumulus did not have as strong
an association with breast cancer in study 1 as previ-
ously reported [13]. This may be due to differences in
the approach used; Eng et al. analysed 414 cases from
one hospital and 685 unmatched controls from a screen-
ing service based in London, adjusting for age, BMI and
reproductive variables in the analysis, whilst we analysed
366 cases using Volpara and Quantra, and 311 using
Cumulus, with 3 well-matched controls per case all re-
cruited from the same screening programme. There
were also a number of differences between the study
populations, with our study population tending to be
younger, with more women of white ethnicity and with
higher BMI and being less likely to be postmenopausal
and to have had children. Density distributions also dif-
fered across the two studies, with the current study hav-
ing lower median (IQR) percent density assessed by
Volpara (4.9, 3.5–7.4) and Quantra (11, 8–14), but
higher percent density for Cumulus (20.3, 11.6–30.3)
[13]. Our version of Volpara was later (1.5.0 vs 1.0) and
we applied a Volpara macro for outlier rejection; our
version of Quantra was also more recent (2.0 vs 1.3). For
Cumulus, the difference might be due to reader
experience.
Study 2 examined the relationship between mammo-
graphic density in mammograms prior to the detection
of cancer, and in matched controls that subsequently
remained cancer free. This enables us to evaluate which
mammographic density methods are most appropriate
for stratifying women attending breast screening. Whilst
visual assessment was most strongly associated with can-
cer, it is unlikely to be used widely for population-based
stratified screening; we conclude that Volpara or Den-
sitas percentage density provide a pragmatic solution.
However, we hypothesise that methods that measure
purely the quantity or relative proportion of dense tissue
do not fully capture the mammographic risk in the same
way as visual assessment by experts, who can see not
only the quantity of dense tissue but the location and
pattern. The addition of algorithms that automatically
quantify mammographic pattern to automated density
software could potentially provide a solution that more
closely reproduces visual assessment. Recent research in
0.5 1 2 5 10
Quintile 5 1.02 (0.67, 1.54)
Quintile 4 0.79 (0.52, 1.18)
Quintile 3 1.04 (0.69, 1.57)
Quintile 2 0.93 (0.62, 1.39)
Quantra    Quintile 1 1.00 (1.00, 1.00)
Quintile 5 2.12 (1.30, 3.45)
Quintile 4 2.10 (1.32, 3.34)
Quintile 3 1.76 (1.10, 2.81)
Quintile 2 1.54 (0.98, 2.41)
Cumulus  Quintile 1 1.00 (1.00, 1.00)
Quintile 5 2.17 (1.41, 3.33)
Quintile 4 1.49 (0.97, 2.30)
Quintile 3 1.86 (1.23, 2.81)
Quintile 2 1.26 (0.83, 1.93)
Densitas  Quintile 1 1.00 (1.00, 1.00)
Quintile 5 2.42 (1.56, 3.78)
Quintile 4 1.61 (1.04, 2.49)
Quintile 3 1.92 (1.26, 2.92)
Quintile 2 1.20 (0.79, 1.82)
Volpara    Quintile 1 1.00 (1.00, 1.00)
Quintile 5 4.37 (2.72, 7.03)
Quintile 4 2.72 (1.68, 4.41)
Quintile 3 2.31 (1.42, 3.76)
Quintile 2 1.94 (1.20, 3.14)
VAS        Quintile 1 1.00 (1.00, 1.00)
Fig. 1 Risk of developing cancer (odds ratios on a logarithm scale) by quintiles of percent density measures in study 1
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this area has proved promising [33–36], although there
is as yet no consensus as to the best method of encapsu-
lating texture information within risk assessment.
Strengths and limitations
The strengths of this study include the ability to assess
the relationship between several measures of mammo-
graphic density and risk of breast cancer. As well as
examining the association between mammographic
density and breast cancer risk, we were able to establish
the temporal relationship in study 2. We also gathered
detailed information in relation to a number of covari-
ates (demographic, hormonal, reproductive, lifestyle and
family history) via a self-reported questionnaire at entry
to PROCAS [20]. Uptake to PROCAS was relatively low
(38%), which may have biased the population to those
with higher or lower risk, for example, the proportion of
women in the PROCAS study who were overweight or
obese was significantly lower than in the general popula-
tion of Greater Manchester [37]. In addition, in study 1,
due to the nature of the study design, whereby controls
had to have had a subsequent cancer-free mammogram
after entry to the PROCAS study, the year of mammo-
gram in controls tended to be earlier than in cases, this
may have had an impact on density measures due to
changes in mammography technology, and the use of
different mammographic machines over time.
Conclusions
Visual assessment of density, recorded on a VAS and av-
eraged between two independent readers, is a strong
predictor of breast cancer risk both in mammograms
taken before the detection of cancer and in images of
the opposite breast at the time of detection. Percentage
density measured by Volpara and Densitas also showed
a strong association with breast cancer risk amongst the
automated measures evaluated, providing practical auto-
mated methods for risk stratification in personalized
screening programmes.
0.5 1 2 5 10
Quintile 5 1.32 (0.85, 2.05)
Quintile 4 1.04 (0.67, 1.62)
Quintile 3 1.03 (0.67, 1.60)
Quintile 2 0.80 (0.53, 1.22)
Quantra    Quintile 1 1.00 (1.00, 1.00)
Quintile 5 2.34 (1.50, 3.68)
Quintile 4 1.79 (1.15, 2.80)
Quintile 3 1.27 (0.80, 1.99)
Quintile 2 1.39 (0.88, 2.19)
Densitas  Quintile 1 1.00 (1.00, 1.00)
Quintile 5 2.87 (1.77, 4.64)
Quintile 4 2.08 (1.32, 3.27)
Quintile 3 1.58 (1.01, 2.45)
Quintile 2 1.42 (0.90, 2.22)
Volpara    Quintile 1 1.00 (1.00, 1.00)
Quintile 5 4.48 (2.79, 7.18)
Quintile 4 2.23 (1.39, 3.57)
Quintile 3 2.11 (1.33, 3.37)
Quintile 2 1.18 (0.72, 1.93)
VAS        Quintile 1 1.00 (1.00, 1.00)
Fig. 2 Risk of developing cancer (odds ratios on a logarithm scale) by quintiles of percent density measures for study 2
Table 4 Matched concordance index (mC)
Study 1 Study 2
mCa 95% CI mCb 95% CI
VAS (%) 0.651 0.611 0.691 0.647 0.607 0.688
Volpara breast density (%) 0.571 0.528 0.618 0.575 0.534 0.615
Volpara gland volume (cm3) 0.553 0.513 0.591 0.586 0.546 0.627
Quantra breast density (%) 0.510 0.469 0.552 0.543 0.504 0.584
Quantra gland volume (cm3) 0.487 0.447 0.528 0.531 0.490 0.574
Densitas breast density (%) 0.571 0.526 0.612 0.587 0.548 0.628
Densitas dense area (cm2) 0.535 0.496 0.574 0.577 0.537 0.616
Cumulus breast density (%) 0.582 0.541 0.623 - - -
Cumulus dense area (cm2) 0.558 0.516 0.599 - - -
CI confidence interval, VAS visual analogue scale
aStudy 1: 239 cases with 3 controls, 62 with 2 controls, 2 with 1 control
bStudy 2: 296 with 3 controls, 31 with 2 controls, 2 with 1 control
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Additional file
Additional file 1: Table S1. Risk of developing breast cancer using
continuous measures of different density methods (OR per SD).
Table S2. P values based on likelihood ratio comparing different models
for density methods using the subset of those with data on all methods.
(DOCX 26 kb)
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